Dublin, Ireland, 21 March 2013 - ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has launched the ICON Signature Series, a new thought leadership program that offers expert insight into value-driven strategies for clinical development.
Built on over 20 years of helping biopharma companies accelerate the development of their drugs, ICON Signature Series brings together ICON and industry experts to share knowledge and expertise across all aspects of clinical development and post-approval strategies. Knowledge will be shared using a broad range of communication channels, including webinars, articles, whitepapers, symposia, workshops and videos. The program also offers an interactive discussion forum for biopharma companies to engage with ICON experts and their industry peers on the latest industry trends and developments.
Commenting on the ICON Signature Series, Dr. Mark Roseman, Executive Vice President, Global Scientific Operations at ICON, said: "Our global team comprises a powerhouse of deep insight in all fields related to clinical R&D. This, coupled with their practical experience in local markets makes them uniquely qualified to offer expert guidance on development practices, comment on emerging issues, and help steer the industry's conversation on its future. The ICON Signature Series will be an invaluable resource to sponsor companies and is part of ICON's on-going commitment to provide clients with strategic development solutions."
The next ICON Signature Series webinar, entitled Enrichment Strategies for achieving greater clinical trial success takes place on 22nd April. Expert Panelists include:
• Mr. Tim Clark, VP Scientific Affairs - ICON Clinical Research
• Professor Klaudius Siegfried - VP CNS - ICON Clinical Research
• Dr. Jamal Gasmi - VP Oncology, ICON Clinical Research
The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in Forms 20-F for the fiscal year ended December 31st 2012 and in the other forms filed with the US Securities and Exchange Commission, including the F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 10,045 employees, operating from 79 locations in 37 countries.
Further information is available at www.iconplc.com